Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 2/20 | 0.41 |
| ▸ | GOPC | Q9HD26 | 2/20 | 0.41 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.37 |
| ▸ | KCNA5 | P22460 | 3/20 | 0.34 |
| ▸ | KCNN4 | O15554 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1243818 | 0.81 | CYP19A1 (0.49) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL2733255 | 0.75 | SMN1; SMN2 (0.40) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL3887188 | 0.72 | CFTR (0.62) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965186 | 0.72 | CYP19A1 (0.43) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL9965131 | 0.70 | CYP19A1 (0.41) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242629 | 0.68 | CYP19A1 (0.57) | CYP19A1KCNA5CYP17A1TSHR | |
| SCHEMBL17714539 | 0.68 | FDPS (0.44) | KDM4EALDH1A1GAA | |
| SCHEMBL1243320 | 0.67 | CYP19A1 (0.44) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1242358 | 0.67 | KCNA5 (0.43) | CFTRGOPCSLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1240803 | 0.67 | KCNA5 (0.52) | SMN1; SMN2KCNA5KDM4EALDH1A1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | claimed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | claimed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | claimed |
| EP-1781635-B1 | POTASSIUM CHANNEL INHIBITORS | MERCK SHARP & DOHME (US) | 2012-06-13 | — | — | EP | disclosed |
| US-7879839-B2 | For treatment and prevention of cardiac arrhythmias; (+-)-2-Morpholin-4-yl-2-phenyl-1,1-dipyridin-3-yl-ethanol; (+-)-2-[(2-methoxyethyl)(methyl)amino]-2-phenyl-1,1-dipyridin-3-ylethanol | MERCK SHARP & DOHME CORP. (US) | 2011-02-01 | — | — | US | disclosed |
| US-20080090794-A1 | Potassium Channel Inhibitors | MERCK SHARP & DOHME LLC | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090794-A1 | Potassium Channel Inhibitors | KCNJ2, KCNQ2, KCNH2 | CFTR 256/4885GOPC 1918/4885SLC6A2 382/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.